Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Cue Biopharma, Inc. (CUE)
Price$27.51Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M | — |
| Research & development | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M | $33.5M | $27.5M | $28.5M | $18.9M |
| Operating expenses | $54.0M | $50.8M | $57.6M | $54.5M | $58.7M | $48.2M | $40.2M | $39.8M | $23.2M |
| Operating income | −$26.6M | −$41.5M | −$52.1M | −$53.2M | −$43.7M | −$45.0M | −$36.8M | −$38.7M | −$23.2M |
| Operating margin | −96.67% | −446.86% | −949.89% | −4,275.10% | −292.56% | −1,427.96% | −1,063.21% | −3,386.71% | — |
| EBITDA | −$25.6M | −$41.1M | −$51.6M | −$52.3M | −$42.5M | −$44.0M | −$36.0M | −$37.9M | −$22.8M |
| EBITDA margin | −93.18% | −442.59% | −939.76% | −4,201.04% | −284.14% | −1,394.44% | −1,039.76% | −3,320.19% | — |
| Net income | −$26.6M | −$40.7M | −$50.7M | −$53.0M | −$44.2M | −$44.8M | −$36.7M | −$39.0M | −$23.2M |
| Net profit margin | −96.85% | −437.97% | −924.10% | −4,257.83% | −295.56% | −1,419.79% | −1,061.18% | −3,411.53% | — |
| Basic EPSper basic share | -$8.40 | -$21.60 | -$33.30 | -$44.70 | -$42.30 | -$46.80 | -$49.80 | -$58.20 | -$64.80 |
| Diluted EPSper diluted share | -$8.40 | -$21.60 | -$33.30 | -$44.70 | -$42.30 | -$46.80 | -$49.80 | -$58.20 | -$64.80 |
Owners
Reported shareholders
7.09%of listed shares
Bleichroeder LP370.68K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Bleichroeder LP | 7.09%370.68K shares |
Lin Shao-Lee | ≈6.26%327.54K shares |
Sarraf Pasha | ≈6.19%323.86K shares |
Driehaus Capital Management LLC | 5.59%292.14K shares |
PASSERI DANIEL R | ≈3.15%164.58K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.09%161.7K shares |
Ikarian Capital, LLC | 2.00%104.36K shares |
Tetragon Partners GP Ltd | 1.79%93.82K shares |
STEMPOINT CAPITAL LP | 1.28%67K shares |
BlackRock, Inc. | 1.11%57.81K shares |
ADAR1 Capital Management, LLC | 1.06%55.19K shares |
Ray Sumita | ≈1.04%54.59K shares |
Lion Point Capital, LP | 1.01%52.93K shares |
Squadron Capital Management LLC | 0.96%50K shares |
DIADEMA PARTNERS LP | 0.92%48.37K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.91%47.82K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.60%31.46K shares |
UBS Group AG | 0.51%26.7K shares |
CITADEL ADVISORS LLC | 0.49%25.63K shares |
VANGUARD FIDUCIARY TRUST CO | 0.47%24.48K shares |
Percentages use 5.23M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 | Lin Shao-LeeChief Executive Officer | BuyCommon Stock Warrants (Right to Buy) · derivative · indirect | 45.5K | — | — | 45.5K |
| Jun 1, 2026Form 4 | Lin Shao-LeeChief Executive Officer | BuyPre-Funded Warrants (Right to Buy) · derivative · indirect | 90.9K | $11.00 | $1000.0K | 90.9K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 77.4K | $0.30 | $23.2K | 323.9K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 78.1K | $0.31 | $24.2K | 246.4K |
| Dec 30, 2025Form 4 | Sarraf PashaDirector | BuyCommon Stock | 86.9K | $0.32 | $27.8K | 168.3K |